Transplant Procedures and Engraftment Data
| Case . | Cytoreductive Regimens . | GVHD Prophylaxis . | Infused Cells . | Use of G-CSF . | Engraftment (d) . | ||||
|---|---|---|---|---|---|---|---|---|---|
| AGC (0.5 × 109/L) . | PLT . | ||||||||
| CD34 (×106/kg) . | CFU-GM (×105/kg) . | CD3 (×105/kg) . | (>20 × 109/L) . | (>50 × 109/L) . | |||||
| 1 | L-PAM (210 mg/m2), BU (16 mg/kg), OKT3 | MPSL | 9.7 | 19.4 | 1.75 | No | 11 | (−) | (−) |
| 2 | TBI (7.5 Gy), ATG (10 mg/kg), CY (200 mg/kg) | CyA + short-term MTX | 3.9 | 11.7 | 0.39 | Yes | 12 | 18 | 19 |
| 3 | TBI (12 Gy), ATG (10 mg/kg), L-PAM (140 mg/m2), TESPA (600 mg/m2) | CyA + short-term MTX | 4.1 | 4.5 | 2.09 | Yes | (−) | (−) | (−) |
| 4 | TBI (10 Gy), AraC (100 mg/m2) cont, HD-AraC (12 g/m2), CY (120 mg/kg), ATG (10 mg/kg) | CyA | 6.4 | 5.4 | 1.07 | Yes | 16 | 23 | 26 |
| 5 | BU (16 mg/kg), AraC (18 g/m2), CY (100 mg/kg) | CyA + short-term MTX | 5.9 | 17.5 | 0.73 | Yes | 20 | 17 | (−) |
| 6 | TBI (12 Gy), CY (120 mg/kg), TESPA (10 mg/kg) | FK506 | 14 | 22.3 | 1.03 | Yes | 14 | 14 | 36 |
| 7 | TBI (12 Gy), VP-16 (60 mg/kg), L-PAM (180 mg/m2) | CyA + short-term MTX | 9.6 | 3.8 | 0.02 | Yes | 9 | 14 | 15 |
| 8 | TBI (12 Gy), CY (200 mg/kg) | CyA + short-term MTX | 7.7 | 1.5 | ND | Yes | (−) | (−) | (−) |
| 9 | TLI (10 Gy), L-PAM (210 mg/m2), BU (600 mg/m2) | CyA + MPSL | 4.7 | 8.8 | 0.58 | No | 9 | 12 | 12 |
| 10 | BU (16 mg/kg), VP-16 (50 mg/kg), L-PAM (140 mg/m2) | CyA + short-term MTX | 11.5 | 16 | 0.05 | Yes | (−) | (−) | (−) |
| 11 | TBI (4 Gy), ALG (1,500 mg), CY (60 mg/kg) | CyA + MPSL | 3.4 | 6.8 | 0.65 | Yes | 16 | 22 | 25 |
| 12 | AraC (12 g/m2), VP-16 (1,600 mg/m2), CY (100 mg/kg) | CyA + short-term MTX | 7.9 | 0.7 | 2.01 | Yes | (−) | (−) | (−) |
| 13 | BU (16 mg/kg), L-PAM (210 mg/m2), TLI (6 Gy) | None | 2.2 | 4.9 | 1.3 | Yes | 19 | 18 | (−) |
| Case . | Cytoreductive Regimens . | GVHD Prophylaxis . | Infused Cells . | Use of G-CSF . | Engraftment (d) . | ||||
|---|---|---|---|---|---|---|---|---|---|
| AGC (0.5 × 109/L) . | PLT . | ||||||||
| CD34 (×106/kg) . | CFU-GM (×105/kg) . | CD3 (×105/kg) . | (>20 × 109/L) . | (>50 × 109/L) . | |||||
| 1 | L-PAM (210 mg/m2), BU (16 mg/kg), OKT3 | MPSL | 9.7 | 19.4 | 1.75 | No | 11 | (−) | (−) |
| 2 | TBI (7.5 Gy), ATG (10 mg/kg), CY (200 mg/kg) | CyA + short-term MTX | 3.9 | 11.7 | 0.39 | Yes | 12 | 18 | 19 |
| 3 | TBI (12 Gy), ATG (10 mg/kg), L-PAM (140 mg/m2), TESPA (600 mg/m2) | CyA + short-term MTX | 4.1 | 4.5 | 2.09 | Yes | (−) | (−) | (−) |
| 4 | TBI (10 Gy), AraC (100 mg/m2) cont, HD-AraC (12 g/m2), CY (120 mg/kg), ATG (10 mg/kg) | CyA | 6.4 | 5.4 | 1.07 | Yes | 16 | 23 | 26 |
| 5 | BU (16 mg/kg), AraC (18 g/m2), CY (100 mg/kg) | CyA + short-term MTX | 5.9 | 17.5 | 0.73 | Yes | 20 | 17 | (−) |
| 6 | TBI (12 Gy), CY (120 mg/kg), TESPA (10 mg/kg) | FK506 | 14 | 22.3 | 1.03 | Yes | 14 | 14 | 36 |
| 7 | TBI (12 Gy), VP-16 (60 mg/kg), L-PAM (180 mg/m2) | CyA + short-term MTX | 9.6 | 3.8 | 0.02 | Yes | 9 | 14 | 15 |
| 8 | TBI (12 Gy), CY (200 mg/kg) | CyA + short-term MTX | 7.7 | 1.5 | ND | Yes | (−) | (−) | (−) |
| 9 | TLI (10 Gy), L-PAM (210 mg/m2), BU (600 mg/m2) | CyA + MPSL | 4.7 | 8.8 | 0.58 | No | 9 | 12 | 12 |
| 10 | BU (16 mg/kg), VP-16 (50 mg/kg), L-PAM (140 mg/m2) | CyA + short-term MTX | 11.5 | 16 | 0.05 | Yes | (−) | (−) | (−) |
| 11 | TBI (4 Gy), ALG (1,500 mg), CY (60 mg/kg) | CyA + MPSL | 3.4 | 6.8 | 0.65 | Yes | 16 | 22 | 25 |
| 12 | AraC (12 g/m2), VP-16 (1,600 mg/m2), CY (100 mg/kg) | CyA + short-term MTX | 7.9 | 0.7 | 2.01 | Yes | (−) | (−) | (−) |
| 13 | BU (16 mg/kg), L-PAM (210 mg/m2), TLI (6 Gy) | None | 2.2 | 4.9 | 1.3 | Yes | 19 | 18 | (−) |
Abbreviations: L-PAM, melphalan; BU, busulfan; CY, cyclopphosphamide; TESPA, thio-tepa; AraC, cytosine arabinoside; ND, not determined; TLI, total lymphoid irradiation.